Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 329-334

  Liu, Tie Fu ^a   Hall, Philip D ^b   Cohen, Kimberley A ^a   Willingham, Mark C ^a   Cai, Jiaozhong ^a   Thorburn, Andrew ^a   Frankel, Arthur E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DAB 389 EGF; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR; HYBRID PROTEIN; NITROGEN; UNCLASSIFIED DRUG; UREA;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY TUBULE NECROSIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; UREA BLOOD LEVEL;

ANIMALS; BLOOD UREA NITROGEN; CELL LINE, TUMOR; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; LIVER; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; NEOPLASM TRANSPLANTATION; NITROGEN; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11344291098     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jernal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
3. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
4. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
5. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168-75.
6. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105-11.
7. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65:27-35.
8. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93-103.
9. Todhunter DA, Hall WA, Rustamzadeh E, et al. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004;17:157-64.
10. Rustamzadeh E, Li C, Doumbia S, et al. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003;65:63-75.
11. Li C, Hall WA, Jin N, et al. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 2002;15:419-27.
12. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2004;65:37-48.
13. Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003;98:584-90.
14. Shaw JP, Akiyoshi DE, Arrigo DA, et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 1991;266:21118-24.
15. Cohen KA, Bissonnette R, Puri RK, et al. Novel fusion protein therapy of refractory brain tumors. Curr Pharm Biotechnol 2003;4:39-49.
16. Liu TF, Cohen KA, Ramage JG, et al. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 2003;63:1834-7.
17. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2003;2:783-7.
18. Hall PD, Kreitman RJ, Willingham MC, et al. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol 1998;150:91-7.
19. Hagihara N, Walbridge S, Olson AW, et al. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 2000;60:230-4.
20. Kihara A, Pastan I. Small chimeric toxins containing only transforming growth factor α and domain III of Pseudomonas exotoxin with good antitumor activity in mice. Cancer Res 1994;54:5154-9.
21. Engebraaten O, Hjortland GO, Juell S, et al. Intratumor immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 2002;97:846-52.
22. Kawkami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 2003;65:15-25.
23. Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
24. Biernat W, Huang H, Yokoo H, et al. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14:131-6.
25. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10:13-5.
26. de Jong MC, Scheffer GL, Broxterman HJ, et al. Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin except when over-expressing the multi-drug resistance protein MRP1. Clin Cancer Res 2003;9:5009-17.
27. Liu TF, Cohen KA, Willingham MC, et al. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J Neurooncol 2003;65:77-85.
28. Liu TF, Willingham MC, Tatter SB, et al. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human gliobiastoma multiforme cells. Bioconjug Chem 2003;14:1107-14.